Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

Presentation TCT 2025

Randomized Comparison of the Supraflex CruzTM vs. SYNERGYTM Drug-Eluting Stents: The Multivessel TALENT Randomized Trial

Presenter: Patrick W. Serruys

October 28, 2025

Presentation TCT 2023

TCT 80: The Everolimus Eluting Synergy MegatronTM Drug-eluting Stent Platform for Aorto-ostial and Proximal Coronary Disease – Early Outcomes from the European Synergy MegatronTM Implanters' Registry

Presenter: Matthew Li Kam Wa

October 26, 2023

Presentation TCT 2022

TCT 159: Percutaneous Coronary Intervention of Large Coronary Vessels with the Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY 4.5/5.0 mm Stent: Primary Outcomes of the EVOLVE Large Vessel Study

Presenter: Elissa Altin

September 19, 2022

Presentation TCT 2022

TCT 14: A 30-day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) Post PCI in Brazil and Japan : SYNERGY Stent with Prasugrel Monotherapy (10 or 3.75 mg )

Presenter: Yoshinobu Onuma

September 17, 2022

Presentation TCT 2020

TCT 381: Predictors of Ischemic and Bleeding Outcomes in High Bleeding Risk Patients Implanted With the SYNERGY Stent – A Post-Hoc Analysis From the EVOLVE Short DAPT Study

Presenter: Robert Yeh

October 14, 2020

Presentation TCT 2020

TCT 262: Percutaneous Coronary Intervention of Long Coronary Lesions With the Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY 48 mm Stent: Primary Outcomes of the EVOLVE 48 Study

Presenter: Dimitri Karmpaliotis

October 14, 2020

Presentation TCT Abstracts Posters 2018

Increased Risk of Acute Stent Thrombosis Associated with Synergy® Bioabsorbable Polymer-Coated Drug-Eluting Stent after Percutaneous Coronary Intervention for Acute Coronary Syndrome

Presenter: Joel Lardizabal

September 25, 2018

Presentation JIM 2018

The Synergy Stent in High Risk Patients: Why Design Matters

Presenter: Giulio G. Stefanini

February 23, 2018

Presentation TCT 2017

Expanding Clinical Evidence With SYNERGY: From EVOLVE II to Real-world Registries and EVOLVE DAPT

Presenter: Ioannis Iakovou, Gert Richardt, Dean J. Kereiakes

October 30, 2017

Presentation JIM 2017

The Synergy Stent: Optimal Healing in Complex Patients

Presenter: Robert A. Byrne

February 10, 2017

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Platinum Chromium Everolimus-Eluting Stents - Evolution From the Fluoropolymer-Based Promus Element to the Bioabsorbable Polymer-Based Synergy

Presenter: Dean J. Kereiakes, Pieter C. Smits

October 30, 2016

Presentation JIM 2016

The Synergy Stent: Optimal In Complex Patients

Presenter: Giulio G. Stefanini

February 10, 2016

Presentation TCT 2015

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

Presenter: Stephen G. Ellis, John A. Ormiston, Dean J. Kereiakes

October 11, 2015

Presentation TCT 2013

SYNERGY Biodegradable Polymer Everolimus Eluting Coronary Stent: Porcine Vascular Compatibility and Polymer Safety Study

Presenter: Gregory Wilson, Angela Marks, Michael Eppihimer, David Knapp, Doug Pennington, Barbara Huibregtse, Keith Dawkins

January 31, 2013

Advertisement

Randomized Comparison of the Supraflex CruzTM vs. SYNERGYTM Drug-Eluting Stents: The Multivessel TALENT Randomized Trial

TCT 80: The Everolimus Eluting Synergy MegatronTM Drug-eluting Stent Platform for Aorto-ostial and Proximal Coronary Disease – Early Outcomes from the European Synergy MegatronTM Implanters' Registry

TCT 159: Percutaneous Coronary Intervention of Large Coronary Vessels with the Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY 4.5/5.0 mm Stent: Primary Outcomes of the EVOLVE Large Vessel Study

TCT 14: A 30-day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) Post PCI in Brazil and Japan : SYNERGY Stent with Prasugrel Monotherapy (10 or 3.75 mg )

TCT 381: Predictors of Ischemic and Bleeding Outcomes in High Bleeding Risk Patients Implanted With the SYNERGY Stent – A Post-Hoc Analysis From the EVOLVE Short DAPT Study

TCT 262: Percutaneous Coronary Intervention of Long Coronary Lesions With the Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY 48 mm Stent: Primary Outcomes of the EVOLVE 48 Study

Increased Risk of Acute Stent Thrombosis Associated with Synergy® Bioabsorbable Polymer-Coated Drug-Eluting Stent after Percutaneous Coronary Intervention for Acute Coronary Syndrome

The Synergy Stent in High Risk Patients: Why Design Matters

Expanding Clinical Evidence With SYNERGY: From EVOLVE II to Real-world Registries and EVOLVE DAPT

The Synergy Stent: Optimal Healing in Complex Patients

Stent Design and Comprehensive Data Review: Platinum Chromium Everolimus-Eluting Stents - Evolution From the Fluoropolymer-Based Promus Element to the Bioabsorbable Polymer-Based Synergy

The Synergy Stent: Optimal In Complex Patients

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

SYNERGY Biodegradable Polymer Everolimus Eluting Coronary Stent: Porcine Vascular Compatibility and Polymer Safety Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content